Mr. Patrick has served as President and Chief Executive Officer of C3J since 2010, and as a member of the board of directors since 2009. Prior to joining C3J, Todd served as President and Chief Operating Officer of ID Biomedical Corporation. Mr. Patrick joined ID Biomedical in 1994 when he became the first employee of the Company’s vaccine subsidiary. Todd remained with ID Biomedical as its President until 2005, when GlaxoSmithKline purchased the Company for $1.5 billion. Upon retiring from ID Biomedical, Mr. Patrick and a group of investors raised over $100 million to invest in several biomedical companies where Todd served as a director and consultant. Before he joined ID Biomedical, Mr. Patrick was appointed as the first Director of the Office of Intellectual Property Administration at UCLA, helping the organization start its IP program in 1989. Mr. Patrick is the past Chairman of the Board of Trustees for the Seattle Biomedical Research Institute, a 400-person, non-profit global health organization focused on creating new drugs and vaccines to treat infectious diseases in the developing world. Todd currently serves on the board of directors of CRH Medical Corporation (NYSE:CRHM); Sunniva, Inc.; Vaxent Vaccines LLC; and InvVax, Inc. He is also on the board of the non-profit Foster Foundation.
Dr. Varnum is a biotech veteran with more than twenty years of experience. Brian began his career with Amgen, and spent more than 18 years at the biotech pioneer as the company grew from a start-up to the largest and most successful biotechnology company. He started in discovery research where his team purified novel growth factors and advanced antibodies and small molecules into clinical studies. Brian also worked in development, assisting with clinical development of proteins, antibodies and small molecules. In this capacity, Brian contributed to key regulatory filings, market research and product launch, giving him experience in drug discovery and development from the lab bench to product launch and marketing. After retiring from Amgen in 2007, Brian turned his focus to the start-up landscape, working in several capacities, including assisting investors, entrepreneurs and start-ups in the assessment of technologies for funding or in-licensing. In these capacities, Brian established research strategies and plans, and served as CSO for several companies, securing funding, and executing research contracts with large and mid-sized pharmaceutical companies. Brian obtained his Ph.D. from UCLA studying oncogenes, and his drug development research experience includes hematopoietic growth factor discovery, oncology, auto-immune/inflammatory disorders, personalized medicine in IBD and infectious diseases.
Mr. Morris leads the production, quality, facilities, and clinical operations areas for C3J. Prior to joining C3J, Mr. Morris was the Chief Operating Officer at Response Biomedical in Vancouver, Canada. While at Response Biomedical, Mr. Morris directed the expansion of manufacturing facilities and scale-up of in vitro diagnostic products. Prior to his tenure at Response, Mr. Morris was responsible for all manufacturing and quality control activities for ID Biomedical Corporation until its acquisition by GlaxoSmithKline (GSK). Mr. Morris was then responsible for all North American Operations which included influenza vaccine production for GSK. Mr. Morris started his career at Syntex Corporation in Palo Alto, where he spent 21 years in increasingly responsible positions, ultimately becoming the Director of Pharmaceutical Manufacturing. Mr. Morris earned his BA in Management from Saint Mary’s College in Moraga, California.
Mr. Goesling has over 30 years of financial and accounting experience with rapidly-growing, technology-based companies deploying new and disruptive technologies. Most recently, Dave has been a consultant for biotechnology and other ventures. Prior to that, Dave was the CFO for RF Surgical Systems, a venture capital backed medical device company that developed and sold the leading system to eliminate retained surgical items, a costly medical error that can occur during surgery. Prior to joining RF Surgical, Dave held finance and accounting positions with increasing levels of responsibility in the telecom industry. He began his career in the auditing group at Deloitte & Touche. Dave currently serves on the Board of Trustees and Finance Committee of the Center for Infectious Disease Research in Seattle, WA. Dave earned a BA in Business Administration – Accounting Concentration from the University of Washington, an MBA degree from the University of Chicago, and achieved a Certified Public Accountant designation.